Almac Sees Profits Increase by 30% as Company Enjoys Record Year
Craigavon-based pharmaceutical development company Almac recorded pre-tax profits of £19.2 million in 2013, up around 30% on the previous year, it has announced.
The company also saw turnover increase, up by 8% from £300 million to £325 million.
Around 3400 people now work for Almac globally, with more than 2000 based at their Craigavon Headquarter site.
Almac provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors including all the world leaders and the company has seen significant growth in the past few years with staff retention rates remaining high.
The company has a major US operation in Pennsylvania and recently opened regional hubs in Singapore and Japan to help service increasing demand for its services in the Asian market.
Alan Armstrong, CEO of Almac, said: “Our long-term objective is to be the leader in our chosen markets and following another successful year I’m pleased to report that we are showing sustained progress in reaching this goal.
“2013 was an exciting year for us with a major jobs boost in Craigavon as we completed a non-GMP drug development facility and expanded our manufacturing capabilities, announced a £13 million investment in cancer research projects with Queen’s University and signed a $9 million deal with Genomic Health securing the rights to further develop and commericalise our breast cancer test.
“We have continued to invest in research and development and capital programmes and this year is set to be another successful one both at our headquarters in Craigavon and globally, following the opening of our new offices in Asia, and looking ahead to the launch of our new facility in Singapore early next year.”
Almac will open a new clinical trial secondary packaging facility in Singapore at the start of next year to better enable just-in-time supply management and support drug pooling strategies, which further optimise the supply chain, minimise wastage and reduce costs.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance